"Pioneering" p53 Reactivator Shows Proof-of-Concept in Phase I Trial

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• The tumor suppressor protein p53 plays a critical role in preventing cancer.
• Mutations in p53 are common in human cancers, leading to loss of its tumor-suppressive functions.
• The Y220C mutation is a specific p53 missense mutation that destabilizes the protein.

Purpose of the Study:

• To evaluate the safety and tolerability of rezatapopt, a novel p53 reactivator.
• To assess the preliminary efficacy of rezatapopt in patients with solid tumors harboring the Y220C p53 mutation.
• To explore the potential of p53 reactivation as a therapeutic strategy in cancer.

Main Methods:

• Phase I clinical trial design.
• Recruitment of patients with advanced solid tumors and documented Y220C p53 mutation.
• Dose escalation and expansion cohorts to determine safety and recommended Phase 2 dose.
• Tumor response assessment using RECIST criteria.

Main Results:

• Rezatapopt was found to be safe and well-tolerated in the study population.
• Objective responses were observed in a subset of patients with Y220C-mutated solid tumors.
• The drug showed lack of efficacy in tumors with KRAS mutations.

Conclusions:

• Rezatapopt demonstrates a promising safety profile and clinical activity in Y220C-mutated solid tumors.
• These findings provide proof of concept for targeting p53 reactivation therapeutically.
• Further investigation is warranted to explore rezatapopt in broader patient populations and common p53 mutations.